We are live on ! Find out more
AI

Allostery Investments Portfolio holdings

AUM $7.85M
This Fund
S&P 500
This Quarter Est. Return
-2.75%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$69.3M
AUM Growth
-$26.4M
Cap. Flow
-$17.7M
Cap. Flow %
-25.58%
Top 10 Hldgs %
65.25%
Holding
56
New
16
Increased
11
Reduced
5
Closed
15

Top Buys

Rank Stock Value
1
MRUS
Merus
MRUS
+$4.49M
2
ABVX
Abivax
ABVX
+$3.44M
3
BBIO icon
BridgeBio Pharma
BBIO
+$2.7M
4
PLRX icon
Pliant Therapeutics
PLRX
+$2.68M
5
PCVX icon
Vaxcyte
PCVX
+$2.56M

Top Sells

Rank Stock Value
1
IONS icon
Ionis Pharmaceuticals
IONS
+$982K
2
DFTX
Definium Therapeutics
DFTX
+$905K
3
DNTH icon
Dianthus Therapeutics
DNTH
+$545K
4
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$496K
5
JSPR icon
Jasper Therapeutics
JSPR
+$470K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QQQ icon
51
PUT
Invesco QQQ Trust
QQQ
$479B
– –
-25,000
Closed -$12.8M
TGTX icon
52
CALL
TG Therapeutics
TGTX
$7.52B
– –
-75,000
Closed -$2.26M
TLT icon
53
PUT
iShares 20+ Year Treasury Bond ETF
TLT
$40.5B
– –
-100,000
Closed -$8.73M
VRDN icon
54
PUT
Viridian Therapeutics
VRDN
$2.61B
– –
-3,600
Closed -$69K
XBI icon
55
CALL
State Street SPDR S&P Biotech ETF
XBI
$10.4B
– –
-175,000
Closed -$15.8M
ZURA icon
56
CALL
Zura Bio
ZURA
$535M
– –
-100,000
Closed -$250K
1 2
3

Similar funds

CP
Castalian Partners Excelsior, Minnesota $7.36M AUM
CAWM
Capital A Wealth Management New Castle, Pennsylvania $8.94M AUM
ADIM
Alpha DNA Investment Management Columbia, Maryland $8.98M AUM 26.05% 1-Year Est. Return
PC
Prysm Capital Princeton, New Jersey $10.6M AUM 2.38% 1-Year Est. Return
AVM
Altos Ventures Management Burlingame, California $11.7M AUM 182.72% 1-Year Est. Return
NP
Newlight Partners New York $3.9M AUM 96.05% 1-Year Est. Return
BPWM
Black Point Wealth Management Naples, Florida $3.5M AUM 16.42% 1-Year Est. Return
CSD
Clear Street Derivatives New York $12.4M AUM 1.7% 1-Year Est. Return

Allostery Investments's Q1 2025 Portfolio in Review

As of Q1 2025, Allostery Investments held 56 positions worth $69.3M, down 28% from $95.7M the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Allostery Investments withdrew a net $17.7M in Q1 2025, closing 15 positions and reducing 5 holdings. Its most notable exit was Definium Therapeutics, an estimated $905K position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 53% a quarter earlier.

Against the trend, Allostery Investments opened a new position in BridgeBio Pharma worth $2.77M.

  • Allostery Investments's largest Q1 2025 buy was BridgeBio Pharma: 80,000 shares worth $2.77M.
  • Allostery Investments added most to Merus in Q1 2025, an estimated $4.49M increase.
  • Allostery Investments's biggest Q1 2025 reduction was Ionis Pharmaceuticals, cutting an estimated $982K.
  • Allostery Investments fully exited Definium Therapeutics in Q1 2025, selling an estimated $905K.
  • Allostery Investments's ten largest holdings make up 65% of its $69.3M portfolio in Q1 2025.
  • Allostery Investments opened 16 new positions and closed 15 in Q1 2025.
  • Allostery Investments's portfolio value fell 28% quarter-over-quarter to $69.3M.

Based on Allostery Investments's 13F filing for Q1 2025, filed 15 May 2025.